BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 35167614)

  • 1. In silico recognition of a prognostic signature in basal-like breast cancer patients.
    Conte F; Sibilio P; Grimaldi AM; Salvatore M; Paci P; Incoronato M
    PLoS One; 2022; 17(2):e0264024. PubMed ID: 35167614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
    Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
    Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. M1 Polarization Markers Are Upregulated in Basal-Like Breast Cancer Molecular Subtype and Associated With Favorable Patient Outcome.
    Hachim MY; Hachim IY; Talaat IM; Yakout NM; Hamoudi R
    Front Immunol; 2020; 11():560074. PubMed ID: 33304345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
    Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
    Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
    Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
    BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative analysis of breast cancer profiles in TCGA by TNBC subgrouping reveals novel microRNA-specific clusters, including miR-17-92a, distinguishing basal-like 1 and basal-like 2 TNBC subtypes.
    Kalecky K; Modisette R; Pena S; Cho YR; Taube J
    BMC Cancer; 2020 Feb; 20(1):141. PubMed ID: 32085745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Essential amino acid metabolism-related molecular classification in triple-negative breast cancer.
    Zhao Y; Pu C; Jiao D; Zhu J; Guo X; Liu Z
    Epigenomics; 2021 Aug; 13(16):1247-1268. PubMed ID: 34448400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer.
    Xie G; Yang H; Ma D; Sun Y; Chen H; Hu X; Jiang YZ; Shao ZM
    Int J Cancer; 2019 Nov; 145(10):2850-2860. PubMed ID: 30977117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
    Karn T; Jiang T; Hatzis C; Sänger N; El-Balat A; Rody A; Holtrich U; Becker S; Bianchini G; Pusztai L
    JAMA Oncol; 2017 Dec; 3(12):1707-1711. PubMed ID: 28750120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach.
    Dessie EY; Tu SJ; Chiang HS; Tsai JJP; Chang YS; Chang JG; Ng KL
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
    Jiang YZ; Ma D; Suo C; Shi J; Xue M; Hu X; Xiao Y; Yu KD; Liu YR; Yu Y; Zheng Y; Li X; Zhang C; Hu P; Zhang J; Hua Q; Zhang J; Hou W; Ren L; Bao D; Li B; Yang J; Yao L; Zuo WJ; Zhao S; Gong Y; Ren YX; Zhao YX; Yang YS; Niu Z; Cao ZG; Stover DG; Verschraegen C; Kaklamani V; Daemen A; Benson JR; Takabe K; Bai F; Li DQ; Wang P; Shi L; Huang W; Shao ZM
    Cancer Cell; 2019 Mar; 35(3):428-440.e5. PubMed ID: 30853353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
    Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
    Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors.
    Sizemore ST; Sizemore GM; Booth CN; Thompson CL; Silverman P; Bebek G; Abdul-Karim FW; Avril S; Keri RA
    Breast Cancer Res Treat; 2014 Jul; 146(1):25-40. PubMed ID: 24847890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A seven-DNA methylation signature as a novel prognostic biomarker in breast cancer.
    Tao C; Luo R; Song J; Zhang W; Ran L
    J Cell Biochem; 2020 Mar; 121(3):2385-2393. PubMed ID: 31646666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a fourteen- innate immunity-related gene pairs signature for predicting prognosis head and neck squamous cell carcinoma.
    Zhang F; Liu Y; Yang Y; Yang K
    BMC Cancer; 2020 Oct; 20(1):1015. PubMed ID: 33081731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiomics analysis reveals CT83 is the most specific gene for triple negative breast cancer and its hypomethylation is oncogenic in breast cancer.
    Chen C; Gao D; Huo J; Qu R; Guo Y; Hu X; Luo L
    Sci Rep; 2021 Jun; 11(1):12172. PubMed ID: 34108519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a DNA Methylation-Based Prognostic Signature for Patients with Triple-Negative Breast Cancer.
    Gao Y; Wang X; Li S; Zhang Z; Li X; Lin F
    Med Sci Monit; 2021 May; 27():e930025. PubMed ID: 34003815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
    Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
    Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of key genes as potential biomarkers for triple‑negative breast cancer using integrating genomics analysis.
    Zhong G; Lou W; Shen Q; Yu K; Zheng Y
    Mol Med Rep; 2020 Feb; 21(2):557-566. PubMed ID: 31974598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico screening using bulk and single-cell RNA-seq data identifies RIMS2 as a prognostic marker in basal-like breast cancer: A retrospective study.
    Zhang L; Liu Z; Zhu J
    Medicine (Baltimore); 2021 Apr; 100(16):e25414. PubMed ID: 33879671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.